Member Info for ThinShins

I remember the question was asked last week if it was confirmed that universal study will be testing for Autoantibodies. Going back through the AGM presentation slides it did clarify the below:

"Assessment of impact of risk factors for a poor outcome:

− Autoantibodies against other type I IFNs (α and ω)

− Presence of naturally occurring antibodies against other type I IFNs associated with a poorer clinical outcome in patients with SARSCoV-2 and more recently flu infections."

@Mani my opinion for whatever it is worth is that because the trial numbers are going to be on the smaller side and recruiting highly targeted patients this wont make much of a difference if it is summer, winter, spring or autumn.

If this was a phase 3 which require large volumes of patients then winter would be ideal due tot he higher influx of hospitalised patients.

From the blogpost from Jan 2023 Prof Tom Wilko mentions "we are bringing together a unique consortium of companies willing to work pre-competitively"

We already know for sure the below are included in the "unique consortium":

Uni of Southampton CTU

Synairgen

Janssen

AstraZeneca

From the UKRI annual report I posted yesterday it mentions:

"Spinout develops faster diagnoses and alternative treatments for lung infections

Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow"

As far as we know Synairgen isn't in the diagnostics business so it leads me to believe there are more players already involved in the consortium Prof TW mentioned, we know Synairgen plans to collaborate with Casanova Labs which would include another partner who will be manufacturing the assays.

Who else could be in this unique concortium? TopMD?

Did we ever get to the bottom of what the below meant from the UKRI Annual Report 2022-2023. very interesting wording.

"Spinout develops faster diagnoses and alternative treatments for lung infections

Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow"

If I remember correctly TommyD was firsy to posy this find on this BB if it was somebody else my apologies.

https://assets.publishing.service.gov.uk/media/64bf8a7fd4051a000d5a9242/ukri-annual-report-accounts-2022-2023-print-ready.pdf

How does the saying go "Set your expectations low, its better to be pleasantly surprised than constantly disappointed"

One thing we know is Synairgen have a track record of not hitting targets and timescales slipping due to things under their control and not under their control, this maybe just how things are in the pharma world and I don't believe SNG have the sway of BP to get things to move quick with regulators etc.

I'm beginning to think the company will be waiting until all data from circa 1,000 subjects has been collected and assessed from UNIVERSAL before starting P2's to give them the fairest shot at cracking the planned trials, personally I'm setting myself up to expect further delays and for the P2s to kick off in early 2025 and if earlier then that is even better.

Who remembers that NDN chap that would endlessly go on about sprinter, cohorts, sub-groups while we were all predicting whether it would be £5-10 a share post sprinter.

Https://www.linkedin.com/posts/mirimus_researchvolunteers-volunteer-medicalresearch-activity-7103389200330223616-55Q4

5 Months ago on linked in: "Join Mirimus research on autoantibodies and help advance medical research"

Mirimus is on the forefront of innovation, exploring autoantibodies, infections, and autoimmune diseases. We're calling on volunteers to contribute to this exciting journey. Your participation could lead to groundbreaking discoveries that shape the future of medicine.

According to the below link Jean-Laurent Casanova has a consulting role or is on the scientific advisory board at Mirimus:

https://rupress.org/jem/pages/editors-and-staff

Eduardo J. Garcia Reino, PhD also is an associate director has link to Rockefeller University which Casanova labs operates out of.

https://www.linkedin.com/in/eduardo-j-garcia-reino-phd-714b0287

Might be something to this.

2024 12 January

- Prof Tom Wilkinson: Developing new approaches to understand and treat inflammatory respiratory disease - a drive for new technology

- Dr Tommaso Morelli: Respiratory viral infections in hospitalised adults - preliminary findings for the UNIVERSAL study

Maybe a stretch but does anybody have University of Southampton credentials to access the below 2 talks held by Prof Tom Wilkinson and Dr Tommaso Morelli which took place on the 12th of Jan 2024?

Would like to see if there was anything new from the universal study shared in these talks.

https://www.southamptonbrc.nihr.ac.uk/brc-forum

Doc.D from the first 313 subjects within the UNIVERSAL Study one thing they did find that they highlighted in the preliminary data:

"Conclusion: Common RVIs including RhV cause considerable morbidity. Lymphopenia and CRP>55 mg/L were associated with more severe disease in adults admitted with RVI. More precise characterisation of biomarkers associated with severity is an essential prerequisite to novel therapeutics development."

Not a clue what it means or if it is even a new finding not already known to the eggheads.

https://thorax.bmj.com/content/78/Suppl_4/A77.2.abstract

Tom Wilkinson @ProfWilko

Just heard the amazing news that the UNIVERSAL respiratory virus study has recruited its 500 subject- amazing progress and halfway to target Many congratulations to all our clinical teams

@UoS_Medicine @SouthamptonBRC @SouthamptonCTU

https://twitter.com/ProfWilko/status/1733150775168114688

Mani seems to be referring to https://www.isrctn.com/ISRCTN49183956 which is sporadically updated and as far as im aware has always shown as no longer recruiting.

Dundee Hospital is also part of recruiting for the UNIVERSAL study, and the below info indicates they are in still active in recruitment up untill end of Jan 2024

https://discovery.dundee.ac.uk/en/projects/understanding-infection-viral-exacerbation-and-respiratory-sympto

Whatever happened with TopMD, I remember Ghia mentioning they were present at the 2022 AGM and that there would be some news to be released about a potential collaboration?

I know this inst the most accurate way of working things out as recruits will fluctuate during seasons but first subject was recruited on 1st September 2022 and reached 500th subject on 8th December 2023. so it took 15 months to recruit 500 subjects which works out 33.333 recruits per month so based on a a rate of 33.33 recruits per month, we could be looking at March 2025 for recruitment to be completed.

Lets hope the recruitment process has been refined and target is reached way sooner.

@jonnyboy33 I dont think the date there is accurate as only last Friday Prof Tom Wilkinson confirmed 500th subject was recruited for the study and the target is 1000 subjects.

https://twitter.com/ProfWilko/status/1733150775168114688

Https://www.isrctn.com/ISRCTN49183956

If you check the bottom editorial notes, you can see it was updated on 14/11/23:

14/11/2023: The overall end date was changed from 17/06/2024 to 17/02/2025.

MrCosts - "Rampers" have quietly dispersed or changed tune. "De-rampers" were proven right . All other investors in between are aware of the reality that this share is in the mud right now. Those who could afford have sold and looked to make a recovery elsewhere and moved on, others who cant afford that have nothing else to do but wait this out and hope that a situation arises where we can at minimum recover our initial investment, close to it or best case scenario make a profit.

The company is small, the company is far from perfect, most investors expect comms that doesn't align with company's comms strategy, there have been mistakes, oversights, slow progress. We all know this, there isn't much we can do except hold on and discuss any updates that have either been found by investors or issued from the company.

The SP is currently 8.75p if it goes to 0p it doesn't make a difference to most that have been holding long term. We either stay in the mud or make progress. You have every right to but complaining on here is not going to achieve anything.

Status: Active

Effective start/end date

1/09/23 → 31/01/24

https://discovery.dundee.ac.uk/en/projects/understanding-infection-viral-exacerbation-and-respiratory-sympto

The below article and quote is from 12th Jan 2023.

“ Due to the winter pressures, Southampton has had a flying start and we are already planning our first read out, which will inform the design of interventional studies, which could launch later this year. Our team of research nurses and doctors, with support from UHS clinical teams, is organised by the Southampton Clinical Trials Unit which is developing a global reputation for expertise in respiratory studies. Although there is no drug involved as yet, the project is funded by close collaboration with industry partners, and we are bringing together a unique consortium of companies willing to work pre-competitively to understand more about this challenge to health.”

https://generic.wordpress.soton.ac.uk/medicallyspeaking/2023/01/12/using-our-expertise-to-help-ease-winter-pressures/